$CRSP
CRISPR Therapeutics AG

2017 Q4 Form 10-K Financial Statement

#000156459019004115 Filed on February 25, 2019

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2017 Q2
Revenue $32.33M $2.387M $3.582M
YoY Change 1305.43% 54.1% 350.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.30M $8.100M $7.800M
YoY Change -6.61% 97.56% -11.36%
% of Gross Profit
Research & Development $20.00M $17.80M $17.12M
YoY Change 28.21% 47.69% 99.02%
% of Gross Profit
Depreciation & Amortization $800.0K $800.0K $700.0K
YoY Change 90.48% 300.0% 600.0%
% of Gross Profit
Operating Expenses $31.35M $25.96M $24.89M
YoY Change 13.19% 60.63% 43.42%
Operating Profit $972.0K -$23.57M -$21.31M
YoY Change 61.33% 28.67%
Interest Expense -$500.0K -$400.0K -$500.0K
YoY Change -98.6% 39900.0% -28.57%
% of Operating Profit -51.44%
Other Income/Expense, Net $0.00 -$100.0K -$666.0K
YoY Change -100.0% 31.58% 9.9%
Pretax Income $600.0K -$24.00M -$21.97M
YoY Change -96.57% 63.42% 28.01%
Income Tax $400.0K $707.0K $343.0K
% Of Pretax Income 66.67%
Net Earnings $140.0K -$24.71M -$22.32M
YoY Change -99.18% 68.3% 30.06%
Net Earnings / Revenue 0.43% -1035.06% -622.98%
Basic Earnings Per Share $0.00 -$0.62 -$0.56
Diluted Earnings Per Share $0.00 -$0.62 -$0.56
COMMON SHARES
Basic Shares Outstanding 40.51M 40.09M 39.90M
Diluted Shares Outstanding 41.64M 40.09M 39.90M

Balance Sheet

Concept 2017 Q4 2017 Q3 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $239.8M $253.5M $272.3M
YoY Change -23.99% 10.89% 10.33%
Cash & Equivalents $239.8M $253.5M $272.3M
Short-Term Investments
Other Short-Term Assets $6.000M $1.900M $2.200M
YoY Change 300.0% 111.11% 120.0%
Inventory
Prepaid Expenses
Receivables $2.626M $3.200M $6.814M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $248.4M $258.6M $281.3M
YoY Change -22.43% 11.63% 12.88%
LONG-TERM ASSETS
Property, Plant & Equipment $18.86M $19.60M $19.93M
YoY Change -10.32% 407.51% 730.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Other Assets $606.0K $3.800M $237.0K
YoY Change 206.06% -2.26% -95.61%
Total Long-Term Assets $22.96M $23.70M $23.69M
YoY Change -7.32% -49.58% -46.04%
TOTAL ASSETS
Total Short-Term Assets $248.4M $258.6M $281.3M
Total Long-Term Assets $22.96M $23.70M $23.69M
Total Assets $271.3M $282.3M $305.0M
YoY Change -21.34% 1.31% 4.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.639M $2.100M $2.559M
YoY Change -64.13% 8.08% -30.84%
Accrued Expenses $11.36M $8.500M $11.89M
YoY Change -30.39% -31.46% -9.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.51M $12.10M $15.81M
YoY Change -34.03% -84.51% -80.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $314.0K $91.20M $198.0K
YoY Change 66.14% 15788.5% -99.74%
Total Long-Term Liabilities $314.0K $91.20M $198.0K
YoY Change 66.14% 15788.5% -99.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.51M $12.10M $15.81M
Total Long-Term Liabilities $314.0K $91.20M $198.0K
Total Liabilities $83.51M $103.4M $107.2M
YoY Change -25.51% -33.56% -32.04%
SHAREHOLDERS EQUITY
Retained Earnings -$125.4M -$100.9M
YoY Change 119.75%
Common Stock $313.3M $298.7M
YoY Change 8.04%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $0.00
YoY Change
Treasury Stock Shares $444.9K 444.9K shares
Shareholders Equity $187.8M $179.0M $197.8M
YoY Change
Total Liabilities & Shareholders Equity $271.3M $282.3M $305.0M
YoY Change -21.34% 1.31% 4.05%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2017 Q2
OPERATING ACTIVITIES
Net Income $140.0K -$24.71M -$22.32M
YoY Change -99.18% 68.3% 30.06%
Depreciation, Depletion And Amortization $800.0K $800.0K $700.0K
YoY Change 90.48% 300.0% 600.0%
Cash From Operating Activities -$14.85M -$15.87M -$15.97M
YoY Change -23.53% 29.34% 17.34%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$2.990M -$1.330M
YoY Change -13.04% 98.01% 26.67%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$500.0K
YoY Change -100.0%
Cash From Investing Activities -$200.0K -$3.490M -$1.330M
YoY Change -101.35% 131.13% 26.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.290M 600.0K 700.0K
YoY Change -98.59% -113.39% -98.85%
NET CHANGE
Cash From Operating Activities -14.85M -15.87M -15.97M
Cash From Investing Activities -200.0K -3.490M -1.330M
Cash From Financing Activities 1.290M 600.0K 700.0K
Net Change In Cash -13.76M -18.76M -16.60M
YoY Change -115.79% 2.74% -135.88%
FREE CASH FLOW
Cash From Operating Activities -$14.85M -$15.87M -$15.97M
Capital Expenditures -$200.0K -$2.990M -$1.330M
Free Cash Flow -$14.65M -$12.88M -$14.64M
YoY Change -23.66% 19.7% 16.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Registrant Name
EntityRegistrantName
CRISPR THERAPEUTICS AG
CY2016 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
185565000
CY2016 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
61929000
CY2016 crsp Issuance Costs For Initial Public Offering In Accounts Payable And Accrued Expenses
IssuanceCostsForInitialPublicOfferingInAccountsPayableAndAccruedExpenses
397000
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5485000
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001674416
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52279167
CY2018Q2 dei Entity Public Float
EntityPublicFloat
2700000000
CY2018Q4 us-gaap Cash
Cash
456649000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.71
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-164428000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
553000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1749000
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-18000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.44
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.89
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40057365
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12257483
CY2016 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1190000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-23177000
CY2018 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2018 dei Entity Small Business
EntitySmallBusiness
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2016 us-gaap Operating Expenses
OperatingExpenses
73294000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-68357000
CY2018 dei Trading Symbol
TradingSymbol
CRSP
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
78512000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-158943000
CY2018 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-4275000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1210000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-197000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1960000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22718000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
45412000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
484000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66608000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
113773000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48294000
CY2017 us-gaap Operating Expenses
OperatingExpenses
105645000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-64648000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-68130000
CY2017 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1763000
CY2016 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-36532000
CY2018Q4 crsp Accrued Expenses Related Parties Current
AccruedExpensesRelatedPartiesCurrent
1700000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-164981000
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47964368
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1240000
CY2018Q4 us-gaap Liabilities
Liabilities
96821000
CY2017Q4 us-gaap Liabilities
Liabilities
83514000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1584000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
489016000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
271346000
CY2017Q4 us-gaap Cash
Cash
239758000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
88000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2626000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9658000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6001000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
466395000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
248385000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18500000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18857000
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
289000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
344000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3163000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3154000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
669000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
606000
CY2018Q4 us-gaap Assets
Assets
489016000
CY2017Q4 us-gaap Assets
Assets
271346000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5069000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1639000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20852000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11361000
CY2018Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
402000
CY2017Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
347000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1202000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1027000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
221000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
137000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27746000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14511000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
57780000
CY2017Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
56928000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
11052000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
11761000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
243000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
314000
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
57000
CY2017Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
682245000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
312018000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-291569000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125440000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
14000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
392195000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
187832000
CY2018Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
88000
CY2017 crsp Research And Development Expense From Related Party
ResearchAndDevelopmentExpenseFromRelatedParty
4523000
CY2016 crsp Research And Development Expense From Related Party
ResearchAndDevelopmentExpenseFromRelatedParty
1755000
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-29124000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
307053000
CY2017Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
821000
CY2017Q4 crsp Accrued Expenses Related Parties Current
AccruedExpensesRelatedPartiesCurrent
0
CY2018Q4 crsp Prepaid Expense And Other Assets Related Parties Current
PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent
3417000
CY2017Q4 crsp Prepaid Expense And Other Assets Related Parties Current
PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent
1871000
CY2018Q4 crsp Contract With Customer Liability Noncurrent With Related Parties
ContractWithCustomerLiabilityNoncurrentWithRelatedParties
57780000
CY2017Q4 crsp Contract With Customer Liability Noncurrent With Related Parties
ContractWithCustomerLiabilityNoncurrentWithRelatedParties
91000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
52183139
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
41092969
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52160798
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41037121
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51852862
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40592248
CY2018Q4 crsp Common Stock Conditional Capital
CommonStockConditionalCapital
20498996
CY2017Q4 crsp Common Stock Conditional Capital
CommonStockConditionalCapital
17338291
CY2018Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
307936
CY2017Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
444873
CY2018 us-gaap Revenues
Revenues
3124000
CY2017 us-gaap Revenues
Revenues
40997000
CY2016 us-gaap Revenues
Revenues
5164000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69800000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42238000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35845000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31056000
CY2018 us-gaap Operating Expenses
OperatingExpenses
162067000
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8050000
CY2016 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
11482000
CY2018 us-gaap Profit Loss
ProfitLoss
-164981000
CY2017 us-gaap Profit Loss
ProfitLoss
-68357000
CY2016 us-gaap Profit Loss
ProfitLoss
-23202000
CY2018 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-22000
CY2017 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
40000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-165003000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68317000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23220000
CY2016 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-25000
CY2018 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
3124000
CY2017 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
4760000
CY2018 crsp Research And Development Expense From Related Party
ResearchAndDevelopmentExpenseFromRelatedParty
23982000
CY2016 crsp Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Shares Value
ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockSharesValue
185565000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
88664000
CY2016 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
82000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10844000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-18000
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
232846000
CY2017 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
59000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2608000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20636000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
40000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
187832000
CY2016 crsp Noncash Contribution Of Intellectual Property To Equity Method Investee
NoncashContributionOfIntellectualPropertyToEquityMethodInvestee
36380000
CY2018 crsp Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
-709000
CY2017 crsp Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
-522000
CY2016 crsp Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
2360000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31884000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
307053000
CY2018 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
249000
CY2017 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
270000
CY2016 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-17000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-96239000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-70093000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52860000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2773000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7814000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3016000
CY2016 crsp Proceeds From Contribution Of Intellectual Property To Equity Method Investee
ProceedsFromContributionOfIntellectualPropertyToEquityMethodInvestee
35000000
CY2016 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
100000
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
113000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8563000
CY2018 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
57000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
39260000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-22000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
392195000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3519000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3024000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
925000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
34985000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
18873000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
10844000
CY2016 us-gaap Paid In Kind Interest
PaidInKindInterest
8050000
CY2017 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
9000
CY2016 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2000
CY2016 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
78608000
CY2018 crsp Income Loss From Equity Method Investments And Investment Compensation Expense
IncomeLossFromEquityMethodInvestmentsAndInvestmentCompensationExpense
-4275000
CY2017 crsp Income Loss From Equity Method Investments And Investment Compensation Expense
IncomeLossFromEquityMethodInvestmentsAndInvestmentCompensationExpense
-1763000
CY2016 crsp Income Loss From Equity Method Investments And Investment Compensation Expense
IncomeLossFromEquityMethodInvestmentsAndInvestmentCompensationExpense
-36380000
CY2018 crsp Non Cash Expense Related To Collaboration Agreement
NonCashExpenseRelatedToCollaborationAgreement
15582000
CY2018 us-gaap Other Noncash Income
OtherNoncashIncome
169000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2538000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-531000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2818000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3342000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4117000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1071000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
12110000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-831000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3860000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-296000
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-20718000
CY2016 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1917000
CY2017 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
500000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2773000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8314000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
89061000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8938000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2608000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
34000
CY2018 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
57000
CY2016 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
1810000
CY2016 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
35010000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
315934000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2608000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
183220000
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-22000
CY2017 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41000
CY2016 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-235000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
216900000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-75758000
CY2016 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
162009000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
242912000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
318670000
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
156661000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
459812000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
334000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7014000
CY2018 crsp Stock Options Issuance Costs
StockOptionsIssuanceCosts
375000
CY2017 crsp Costs For Proposed Supplemental Offering In Accounts Payable And Accrued Expenses
CostsForProposedSupplementalOfferingInAccountsPayableAndAccruedExpenses
290000
CY2016 crsp Property And Equipment Related To Lease Incentives
PropertyAndEquipmentRelatedToLeaseIncentives
10785000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
50581000
CY2018 crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
2400000
CY2017 crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
1200000
CY2018 crsp Cost Sharing Expenses Accrued
CostSharingExpensesAccrued
1900000
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-balance Sheet Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash. The Company&#8217;s cash is held in accounts with financial institutions that management believes are creditworthy. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss. </p>
CY2017 crsp Cost Sharing Expenses Accrued
CostSharingExpensesAccrued
400000
CY2016 crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
2800000
CY2018 crsp Joint Venture Agreement Date
JointVentureAgreementDate
2015-12-19
CY2016Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
35000000
CY2016Q4 us-gaap Equity Method Investments
EquityMethodInvestments
36500000
CY2016Q4 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
170689
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018Q4 crsp Uncertain Tax Position Recognized
UncertainTaxPositionRecognized
0
CY2016Q4 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
0
CY2018 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each Common Share
CY2018 us-gaap Dividends
Dividends
0
CY2018 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2013-10-28
CY2018 dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Basel, Switzerland
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
456600000
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
239800000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
456649000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
239758000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
315520000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3163000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3154000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3150000
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2017 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2016 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
6275000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
6866000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
7072000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
5874000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
5855000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
18639000
CY2017Q4 crsp Uncertain Tax Position Recognized
UncertainTaxPositionRecognized
0
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7016653
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6419854
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4624738
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25875000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22768000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7375000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3911000
CY2018 us-gaap Depreciation
Depreciation
3500000
CY2017 us-gaap Depreciation
Depreciation
3000000
CY2016 us-gaap Depreciation
Depreciation
900000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7321000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5550000
CY2018Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
7973000
CY2017Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2285000
CY2018Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
625000
CY2017Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
609000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1848000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2176000
CY2018Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
2193000
CY2017Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
500000
CY2018Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
294000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
598000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
241000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
5700000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
6900000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
4200000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39260000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20636000
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
83300000
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
366401
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
251500
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
246286
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
44273
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
327342
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.094
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.168
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.003
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.026
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.021
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25418000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.014
CY2017 crsp Effective Income Tax Rate Reconciliation Statutory Permanent Differences
EffectiveIncomeTaxRateReconciliationStatutoryPermanentDifferences
0.018
CY2016 crsp Effective Income Tax Rate Reconciliation Statutory Permanent Differences
EffectiveIncomeTaxRateReconciliationStatutoryPermanentDifferences
0.066
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.029
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.049
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.018
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1816000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
3300000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.008
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.031
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.141
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
600000
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
500000
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
5966000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
5184000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
3322000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-170394000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-71792000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-26040000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-164428000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-66608000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-22718000
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
416000
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1533000
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
649000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
131000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
42000
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-11000
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-6000
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-17000
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
547000
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1569000
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
621000
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
6000
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
477000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-30000
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-297000
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-105000
CY2016 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-2000
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
6000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
180000
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-137000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.093
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.093
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.103
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.007
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.003
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.013
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.016
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.004
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.025
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.033
CY2018 crsp Effective Income Tax Rate Reconciliation Statutory Permanent Differences
EffectiveIncomeTaxRateReconciliationStatutoryPermanentDifferences
0.010
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
51000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2871000
CY2018Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
3264000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3322000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-28300000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
40042000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
36208000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26997000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-28300000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3834000
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
3785000
CY2018Q1 us-gaap Revenues
Revenues
1358000
CY2018Q2 us-gaap Revenues
Revenues
1088000
CY2018Q3 us-gaap Revenues
Revenues
563000
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
CY2018Q4 us-gaap Revenues
Revenues
115000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
28355000
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
CY2018Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
49000
CY2018Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
22000
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3856000
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
22000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9987000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1123000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
3494000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
36000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1721000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
543000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
16904000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13041000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3863000
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
3791000
CY2017Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
59000
CY2017Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
31000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3881000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
18000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
541100000
CY2018 crsp Operating Loss Carryforwards Expiration Period
OperatingLossCarryforwardsExpirationPeriod
2020
CY2018Q4 crsp Deferred Tax Assets Operating Loss Carryforwards Domestic State Research And Development
DeferredTaxAssetsOperatingLossCarryforwardsDomesticStateResearchAndDevelopment
1800000
CY2018 crsp Research And Development Credit Carryforwards Expiration Period
ResearchAndDevelopmentCreditCarryforwardsExpirationPeriod
2033
CY2018Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
700000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1595000
CY2018Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1500000
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 crsp Uncertain Tax Position Recognized
UncertainTaxPositionRecognized
0
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
354000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
163000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
49000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1212000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
178000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
134000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
29000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
13000
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
20000
CY2017Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41635843
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
CY2018Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45877428
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46842316
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47391988
CY2018Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51688383
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45877428
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46842316
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47391988
CY2018Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51688383
CY2017Q1 us-gaap Revenues
Revenues
2703000
CY2017Q2 us-gaap Revenues
Revenues
3582000
CY2017Q3 us-gaap Revenues
Revenues
2387000
CY2017Q4 us-gaap Revenues
Revenues
32325000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
23447000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
24888000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
25957000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
31353000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-20744000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21306000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23570000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
972000
CY2017Q1 us-gaap Profit Loss
ProfitLoss
-21475000
CY2017Q2 us-gaap Profit Loss
ProfitLoss
-22315000
CY2017Q3 us-gaap Profit Loss
ProfitLoss
-24707000
CY2017Q4 us-gaap Profit Loss
ProfitLoss
140000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-21475000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-22315000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-24707000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
140000
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39725947
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39895938
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40088718
CY2017Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40509897
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39725947
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39895938
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40088718

Files In Submission

Name View Source Status
0001564590-19-004115-index-headers.html Edgar Link pending
0001564590-19-004115-index.html Edgar Link pending
0001564590-19-004115.txt Edgar Link pending
0001564590-19-004115-xbrl.zip Edgar Link pending
crsp-10k_20181231.htm Edgar Link pending
crsp-20181231.xml Edgar Link completed
crsp-20181231.xsd Edgar Link pending
crsp-20181231_cal.xml Edgar Link unprocessable
crsp-20181231_def.xml Edgar Link unprocessable
crsp-20181231_lab.xml Edgar Link unprocessable
crsp-20181231_pre.xml Edgar Link unprocessable
crsp-ex1016_355.htm Edgar Link pending
crsp-ex211_6.htm Edgar Link pending
crsp-ex231_18.htm Edgar Link pending
crsp-ex232_19.htm Edgar Link pending
crsp-ex311_9.htm Edgar Link pending
crsp-ex312_10.htm Edgar Link pending
crsp-ex321_12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
guve0pd5dhxm000001.jpg Edgar Link pending
guve0pd5dhxm000002.jpg Edgar Link pending
guve0pd5dhxm000003.jpg Edgar Link pending
guve0pd5dhxm000004.jpg Edgar Link pending
guve0pd5dhxm000005.jpg Edgar Link pending
guve0pd5dhxm000006.jpg Edgar Link pending
guve0pd5dhxm000007.jpg Edgar Link pending
guve0pd5dhxm000008.jpg Edgar Link pending
guve0pd5dhxm000009.jpg Edgar Link pending
guve0pd5dhxm000010.jpg Edgar Link pending
guve0pd5dhxm000011.jpg Edgar Link pending
guve0pd5dhxm000012.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending